Eltrombopag Diolamine

艾曲波帕乙醇胺

Report date: 2026/04/24 20:01:59
NME

Base Information

Drug NameEltrombopag Diolamine
Drug Alias Name伊屈泼帕eltrombopagumeltrombopag依琼珀Eltrombopag Olamine +[17] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionThrombopoietin receptor agonists
TargetsThrombopoietin receptor
Therapy Area/IndicationsBone marrow transplant rejectionSolid tumoursHemorrhage +[43] 
Global Approved IndicationsPurpura, Thrombocytopenic, Idiopathic
Approved Indications in ChinaPurpura, Thrombocytopenic, Idiopathic
Original Approved Country/TerritoryUnited States
Original Approved Date2008/11/20
Country/TerritoryCzechiaBelgiumBulgaria +[48] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcNovartis Pharma Schweiz AgNovartis Pharma Ag +[13] 
Inactive CompaniesUtah State UniversityDana-Farber Cancer InstituteUniversity of Texas Southwestern Medical Center +[18] 
Active IndicationsBone marrow transplant rejectionPrimary MyelofibrosisMyelodysplastic Syndromes +[18] 
Inactive IndicationsSolid tumoursHemorrhageDelayed Graft Function +[25] 

Other Information

ATC CodeB02BX05
Related LinksWikipediaDrugBankKEGG